Children's National Medical Center(5.4 mi away)Contact
+32 other location
graft versus host disease
granulocyte colony stimulating factor
minimal residual disease
left ventricular fractional shortening
This is a pilot study utilizing Marqibo (vincristine sulfate liposome injection) combined
with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute
lymphoblastic leukemia (ALL).
This study will utilize Marqibo as a replacement for standard vincristine in combination
with chemotherapy for children with relapsed ALL. The hypothesis is that the incorporation of
Marqibo with combination chemotherapy will be safe and feasible. In the context of this
pilot study, overall outcomes and efficacy will be a secondary objective. It is hypothesized
that data from this combination may show improved efficacy including, complete remission
(CR), minimal residual disease (MRD) negativity, and progression free survival (PFS) rates
and safety (i.e., neurotoxicity) in comparison to outcomes in historical regimens, including
the UK ALL R3 with standard vincristine.
Marqibo in combination with UK ALL R3,
Clinical Study Identifier
Therapeutic Advances in Childhood Leukemia Consortium
Last Modified on
6 May 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.